From the Department of Gastroenterology, SMS Medical College and Hospital.
Department of Radiology, Santokba Durlabhji Memorial Hospital, Jaipur, India.
Pancreas. 2024 Apr 1;53(4):e330-e337. doi: 10.1097/MPA.0000000000002303. Epub 2024 Feb 12.
Pseudoaneurysm usually occurs after vascular injuries or erosions such as in trauma or inflammation like pancreatitis and is associated with high morbidity and mortality.
The aim of study is to assess efficacy and safety of EUS-guided thrombin injection in pseudoaneurysm.
Prospective data collection was done at SMS Hospital, Jaipur, from January 2015 to March 2023. All patients with pseudoaneurysm were consecutively enrolled.
Twenty patients (M/F, 18:2) with median age of 41 years (25-58 years), were studied. Underlying etiology of pseudoaneurysm was chronic pancreatitis in 75% of the patients, blunt trauma abdomen in 15% of the patients, recurrent acute pancreatitis in 5%, and idiopathic in 5% of the patients. At the time of admission, mean hemoglobin was 6.7 g/dL (3.4-8.2), with median blood transfusion requirement was 2 units (0-6 units). Hemoglobin values after 4-6 weeks showed a significant improvement ( t = 9.21, P < 0.05).Mean dose of human thrombin required for complete obliteration of pseudoaneurysm was 520 ± 188.6 IU per patient (300-800 IU). Amount of thrombin (IU) dose needed to achieve complete obliteration correlated well significantly with the dimension of pseudoaneurysm, P value less than 0.05 ( R = 0.80). Median follow-up duration in this study was 44 months (3-84 months), which was the longest follow-up period by far.
Endoscopic ultrasound-guided thrombin injection in visceral artery pseudoaneurysm is a safe and effective alternative for patients not amenable for digital subtraction angiography-guided angioembolization.
假性动脉瘤通常发生在血管损伤或侵蚀后,如创伤或胰腺炎等炎症,其发病率和死亡率都很高。
本研究旨在评估超声内镜引导下凝血酶注射治疗假性动脉瘤的疗效和安全性。
本前瞻性研究于 2015 年 1 月至 2023 年 3 月在斋浦尔 SMS 医院进行,连续纳入所有假性动脉瘤患者。
20 例患者(男/女,18:2),中位年龄 41 岁(25-58 岁)。假性动脉瘤的潜在病因中,75%为慢性胰腺炎,15%为腹部钝性创伤,5%为复发性急性胰腺炎,5%为特发性。入院时,平均血红蛋白为 6.7g/dL(3.4-8.2),中位输血需求为 2 单位(0-6 单位)。4-6 周后血红蛋白值显著改善( t = 9.21,P < 0.05)。每个患者完全闭塞假性动脉瘤所需的人凝血酶平均剂量为 520±188.6IU(300-800IU)。需要的凝血酶(IU)剂量与假性动脉瘤的大小显著相关,P 值小于 0.05( R = 0.80)。本研究的中位随访时间为 44 个月(3-84 个月),这是迄今为止最长的随访时间。
对于不适合数字减影血管造影引导血管栓塞的患者,内镜超声引导下凝血酶注射治疗内脏动脉假性动脉瘤是一种安全有效的替代方法。